our papers

Please see an up-to-date list of citations here.

Alice's Google Scholar profile can be found here and her C.V. can be found here.


One silver lining from COVID19: Most talks are virtual! Alice's talk, on "How we move towards molecular definition in Parkinson's Disease" (from the Grand Challenges in PD meeting hosted by the Van Andel Research Institute in September 2020) can be found here.

Our newest paper:
"GPNMB confers risk for Parkinson's disease through interaction with α-synuclein," by Maria Diaz-Ortiz, Yunji Seo, et al. can be found here or here.

This is the author’s version of the work. It is posted here by permission of the AAAS for personal use, not for redistribution. The definitive version was published in Science on August 19, 2022, DOI: 10.1126/science.abk0637.

There are also the things we learned the hard way. And other useful stuff.

Some experiments work out the way that you expect. Some do not. Some projects are publishable. Some are not.

Here is a place we are putting data that we think is valuable, but not publishable. Some of it is negative data (e.g. biomarkers that did not replicate). Some of it is data that is too confusing (e.g. things that are too noisy to translate clinically). Some of it is information that you may just want (e.g. quality control procedures, experience with various assays, slides from talks).

A quick guide to the files you can access below:

(1) MJFF PPMI data-May2015: This is a set of slides showing our data for measures of epidermal growth factor (EGF) and apolipoprotein A1 (ApoA1) in plasma samples from the international Michael J. Fox Foundation Parkinson's Progression marker Initiative cohort. EGF measures vary greatly by clinical site of origin, even with the rigorous standard operative procedures that PPMI uses. In these same samples, ApoA1 measures, in contrast, do not. Bottom line is that from the perspective of biomarker development, some proteins will be better candidates by virtue of their stability to variation in sample collection/storage/processing.

(2) Somalogic Slides: Quality control data from our experience with the Somalogic aptamer platform. The first slide shows the analytes that "failed" quality control (>20% CV across any of three sets of triplicates -- 9 QC samples total = 3 sets x 3 triplicates). The second slide shows whether the three sets of triplicates overlapped with respect to "failures." The third and fourth slides show whether the Somalogic platform performs similarly across space (Penn vs. Boulder) and time (2013 vs. 2015).

(3) Derek Denny Brown lecture slides: These are from Alice's presentation in October 2018 when she was awarded the Derek Denny Brown Award from the American Neurological Association. They provide an overview of what the lab was doing in its first 8 years.

MJFF PPMI data-May2015.pptx
SomalogicSlides.pdf
TowardsTranslationDDB-NoHidden.pdf